Talis Biomedical Corp. (TLIS): Bagan rega target

The current market value of Talis Biomedical (TLIS) shown on this chart is currently 4.98. The business is optimizing sample delivery through rapid tests, which increases profit for medical centers. The Talis One system ensures high accuracy for infection analysis directly within the clinic. However, management is currently liquidating the company due to a failed strategy, and investors have completely lost faith in the asset.

The consensus forecast reflects the market's average expectation for the asset's fair value, based on the business's ability to maintain margins under inflationary pressure. By analyzing the aggregate target valuations from investment banks, investors can see how models react to financial reports; for Talis Biomedical (TLIS), this confirms the potential for recurring revenue from the sale of disposable cartridges, which guarantees a stable free cash flow.